Skip to main content

Monoclonal Antibodies

Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma

Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies

Christopher Sinoimeri, PharmD; Bryan Do, PharmD, BCOP; Sheree Chen, PharmD, BCOP

Phase 1/2 Study Results of BCMA x CD3 Bispecific Monoclonal Antibody REGN5458 in Patients with RRMM

In Patients with RRMM, REGN5458, a BCMA × CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses

HORIZON: Use of Melflufen plus Dexamethasone in Patients with RRMM Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

Sterility Duration of Single-Use Vials for Antineoplastic Agents or Monoclonal Antibodies Extended with a Closed-System Transfer Device

Major Rosalynda Uy, PharmD, BCPS; Michael S. Edwards, PharmD, MBA, BCOP, FASHP; Dominic A. Solimando, Jr, MA, BCOP, FAPhA, FASHP

Role of Pharmacist Intervention in the Safe Administration of Anti-CD20 Monoclonal Antibodies

Hayley Ann Hodgson, PharmD; Arpita S. Gandhi, PharmD, BCOP; Stephen Michael Clark, PharmD, BCOP

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma

1
2

Page 2 of 2
Results 11 - 19 of 19